CLINICAL TRIAL SUMMARY

MDACC Study No:2009-0179 (clinicaltrials.gov NCT No: NCT00966693)
Title:Phase I/II Study of Lenalidomide (Revlimid), Thalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Principal Investigator:Jatin J. Shah
Treatment Agent:Dexamethasone; Lenalidomide; Thalidomide
Study Status:Closed
Study Description:The goal of the Phase I portion of this clinical research study is to find the
highest tolerated dose of the combination of thalidomide, lenalidomide, and
dexamethasone that can be given to patients with relapsed or refractory MM.

The goal of the Phase II portion of this study is to learn if the drug
combination can help to control the disease.

The safety of the drug combination will be studied in both phases.

Hide details for General InformationGeneral Information

Disease Group:Myeloma
Phase of Study:Phase I/Phase II
Treatment Agents:Dexamethasone
Lenalidomide
Thalidomide
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:none
Supported By:Celgene Corporation
Return Visit:During Cycle 1 patients will return to clinic weekly and all other cycles
patients will return monthly.
Home Care:No home care required.


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jatin J. Shah
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults